A5018431544- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis C virus research
- Liver Disease and Transplantation
- Hepatitis B Virus Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Mechanisms and Therapy
- Nutrition and Health in Aging
- Enzyme Production and Characterization
- Renal cell carcinoma treatment
- Liver Diseases and Immunity
- Peptidase Inhibition and Analysis
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
- Systemic Lupus Erythematosus Research
- HIV/AIDS drug development and treatment
- Liver physiology and pathology
- Phytase and its Applications
- Diet, Metabolism, and Disease
- Lung Cancer Treatments and Mutations
- Lymphoma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Research Studies
- Plant Disease Resistance and Genetics
- Hepatitis Viruses Studies and Epidemiology
Hiroshima University
2014-2023
Hiroshima University Hospital
2013-2022
Life Science Institute
2014-2021
California Liver Research Institute
2021
Hiroshima Bunkyo University
2020
Shinshu University
2019
Committee on Publication Ethics
2016
Hyogo Medical University
2016
Kawasaki Medical School
2016
The University of Tokyo
2016
Sarcopenia is defined by muscle loss and dysfunction. classified into primary secondary types, based on the cause. Primary sarcopenia mainly aging-related sarcopenia, whereas reduced mass strength that accompanies an underlying disease. Given essential role of liver in metabolism, due to nutritional disorders or other factors can frequently occur In 2015, Japan Society Hepatology (JSH) decided establish its own assessment criteria for disease because number patients with expected increase...
To compare the efficacy and safety of edoxaban warfarin for treatment portal vein thrombosis (PVT) following danaparoid sodium in patients with liver cirrhosis.Fifty cirrhotic PVT treated initially 2 weeks were enrolled this retrospective cohort study. Treatment was later switched to either (n = 20) or 30). We compared up 6 months. The volume measured by dynamic computed tomography before treatment, at weeks, 1, 3, months.There no significant differences clinical characteristics two groups....
To compare the tumor control and safety of stereotactic body radiation therapy (SBRT) combined with transcatheter arterial chemoembolization (TACE) for small, solitary, hypervascular hepatocellular carcinoma (HCC) TACE alone.Three hundred sixty-five HCC patients who had ≤ 3 cm, nodule were treated TACE. Among them, 30 followed by SBRT (SBRT group) 38 without additional previous treatment (control enrolled in this retrospective cohort study. Local progression, complication, disease-free...
Aim: In this study, we evaluated the clinical characteristics of hepatocellular carcinoma (HCC) because etiology HCC has been changing recently. Methods: Consecutive 1374 patients at our institution from 1995 to 2009 were enrolled and investigated. Results: Seventeen percent 67% related hepatitis B virus (HBV‐HCC) C (HCV‐HCC), respectively. Fifteen that was negative for surface antigen (HBsAg) antibody (HCVAb) (NBNC‐HCC). HCV‐HCC tended decrease NBNC‐HCC increase in recent years. Patients...
Although interferon (IFN)-free antiviral therapy is expected to improve the treatment response for chronic hepatitis C, effect on liver function and fibrosis unknown. In this study, we analyzed long-term follow up of parameters markers in genotype 1b C virus (HCV)-infected patients treated with daclatasvir asunaprevir.Thirty were asunaprevir 24 weeks, 26 achieved sustained virological (SVR). We measured parameters, serum alanine aminotransferase (ALT) albumin levels markers, hyaluronic acid,...
Abstract Aim Sarcopenia has a high prevalence and can be an adverse predictor in patients with chronic liver diseases (CLDs). We sought to assess the of sarcopenia its prognostic significance CLDs at multiple centers Japan. Methods In this retrospective study, we collated data 1624 (976 men). The diagnosis was determined by assessment criteria Japan Society Hepatology. Predictors mortality were identified using univariate multivariate analyses. Results Muscle weakness skeletal muscle loss...
Although the effect of levocarnitine (L-carnitine) on hyperammonemia has been reported in patients with liver cirrhosis (LC), its sarcopenia remains to be elucidated. We assessed effects L-carnitine LC. retrospectively evaluated 52 LC who were treated for more than 3 months between February 2013 and June 2017. Computed tomography was used measure cross-sectional area skeletal muscles at level third lumbar vertebra. The relative change muscle index (SMI) per year (ΔSMI/year) computed each...
<b><i>Introduction:</i></b> We evaluated the efficacy and safety of lenvatinib-transcatheter arterial chemoembolization (LEN-TACE) sequential therapy for patients (<i>n</i> = 88) with intermediate-stage hepatocellular carcinoma (HCC). <b><i>Methods:</i></b> Eighty-eight who obtained tumor control by LEN treatment were analyzed; 30 received followed TACE (LEN-TACE therapy), 58 monotherapy. Propensity score matching was performed,...
Abstract Background and Aims: We evaluated the prognosis associated factors in patients with small hepatocellular carcinoma (HCC; up to 3 nodules, each 3cm diameter) treated percutaneous radiofrequency ablation (RFA) as first‐line treatment. Methods: Eighty‐eight consecutive who underwent RFA treatment were enrolled, among whom 70 had hypervascular HCC nodules which by a combination of transcatheter arterial chemoembolization RFA. was repeated until an ablative margin obtained. Results: The...
To compare the assessment of response and prognosis patients to sorafenib treatment by Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), α-fetoprotein (AFP) des-γ-carboxy prothrombin (DCP).Sixty-six with advanced hepatocellular carcinoma (HCC) treated were enrolled this retrospective study. The was evaluated RECIST, mRECIST changes AFP DCP.The median survival time all 8.6 months. radiological progression 3.3 rates [complete (CR) + partial (PR)] 3.0 9.0%,...
Steatosis is a common histological feature of chronic liver disease, especially alcoholic and non-alcoholic fatty as well hepatitis C. A recent study showed that evaluating the controlled attenuation parameter (CAP) with transient elastography was an efficient way non-invasively determining severity hepatic steatosis. The objective this to prospectively evaluate utility CAP for diagnosing steatosis in patients disease.One hundred fifty-five consecutive suspected disease underwent diagnosis...
We assessed the risk factors for development of hepatocellular carcinoma (HCC) following successful eradication hepatitis C virus (HCV) with interferon (IFN) therapy in a long-term, large-scale cohort study.We reviewed 1094 consecutive patients HCV who achieved sustained virological response (SVR) IFN between January 1995 and September 2013.During observation period (median 50 months: range 13-224), 36 (3%) developed HCC after SVR. The median from SVR to diagnosis was 37 months (range...
The risk of hepatocellular carcinoma (HCC) development is reduced following viral elimination by interferon therapy in chronic hepatitis C patients. However, the patients treated with interferon-free direct-acting antivirals (DAAs) unknown. We evaluated who achieved eradication pegylated-interferon plus ribavirin (PEG-IFN/RBV, n = 244) or daclatasvir asunaprevir (DCV/ASV, 154) therapy. None had prior history HCC antiviral median observation period after end treatment for PEG-IFN/RBV and...
This study investigated early tumor marker response and treatment in patients with advanced hepatocellular carcinoma (HCC) treated lenvatinib.Twenty HCC who received lenvatinib were enrolled this retrospective study. α-Fetoprotein (AFP) des-γ-carboxyprothrombin (DCP) levels measured before as well 2 4 weeks after treatment. The objective rate was evaluated by mRECIST at 6 weeks.The 30% (complete response/partial response/stable disease/progressive disease: n = 0/6/6/8 cases) mRECIST. At...
OBJECTIVES: Biomarkers for optimizing the outcome of treatment with lenvatinib in patients advanced hepatocellular carcinoma remain to be established despite intensive and comprehensive genomic research. Lenvatinib is characterized by its prominent inhibitory potency fibroblast growth factor receptor (FGFR) 4 compared earlier tyrosine kinase inhibitors. Thus, this study, we focused on simplified quantification FGFR4 tumors as a potential predictive indicator. METHODS: According The Cancer...
Overall survival of patients with advanced hepatocellular carcinoma (HCC) Vp4 (tumor thrombosis the main trunk or bilobar portal vein) is extremely poor.The purpose this study to clarify prognosis hepatic arterial infusion chemotherapy (HAIC) combined radiation therapy (RT) for HCC and analyze factors that contribute prognosis.In retrospective cohort study, 51 who were treated HAIC RT vein tumor met following criteria enrolled: (i) Vp4; (ii) Child-Pugh score 5-7; (iii) Eastern Cooperative...
We compared the treatment response, survival, and safety to hepatic arterial infusion chemotherapy (HAIC) in patients with advanced hepatocellular carcinoma (HCC) according Child-Pugh (CP) score.The study subjects were 249 HCC CP class A B who had been treated HAIC. Patients grouped score (5/6, 7 8/9) their tumor tolerance, survival assessed.The median time (MST) was 8.2, 9.7, 6.3, 3.9 months for whole group, 5/6, 8/9, respectively (P < 0.0001). Complete response (CR) partial (PR) seen 11 57...
Objectives Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and those refractory to transcatheter arterial chemoembolization (TACE) or macroscopic vascular invasion (MVI). The application of sorafenib has been approved by Japanese Government‐sponsored Medicare HCC. In this retrospective cohort study we aimed compare various aspects HAIC in Child–Pugh A patients HCC who were otherwise free extrahepatic metastasis....
Aim As second‐line therapy, regorafenib has been shown to provide a survival benefit for patients with hepatocellular carcinoma (HCC) who progress on sorafenib. In this retrospective study, we assessed the clinical outcomes of sorafenib treatment failure regard chemotherapy. Methods Patients ( n = 160) advanced HCC, Child–Pugh A liver function and Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1 treated between June 2009 September 2016 were enrolled. Among 147 progressive...
To assess the efficacy and safety of anticoagulant drug, danaparoid sodium, in treatment portal vein thrombosis (PVT) patients with liver cirrhosis.A consecutive 26 cirrhotic PVT were enrolled this retrospective cohort study. The etiologies cirrhosis hepatitis B virus-related, C alcoholic cryptogenic five, 14, three four patients, respectively. Child-Pugh grade A, was noted 13, eight five Patients treated 2 weeks' administration sodium followed by evaluation reduction adverse events.All...
<b><i>Objective:</i></b> To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT). <b><i>Methods:</i></b> This retrospective study included 108 HCC PVTT main trunk or first branch Child-Pugh ≤7. Sixty-eight received HAIC RT 40 sorafenib. Patients were then assigned to group...
Background and aims The feature of blood glucose dynamics in patients with chronic liver disease (CLD) is marked fluctuations. However, the detail not well known. aim present study was to evaluate glycemic fluctuations by continuous monitoring (CGM). Materials methods A total 105 CLD type 2 diabetes mellitus (T2DM) were enrolled this study. Various parameters variability evaluated. association these functional reserve examined. also evaluated according glycated hemoglobin A1c (HbA1c) levels....